Matuszczak Milena, Kiljańczyk Adam, Marciniak Wojciech, Derkacz Róża, Stempa Klaudia, Baszuk Piotr, Bryśkiewicz Marta, Cybulski Cezary, Dębniak Tadeusz, Jacek Gronwald, Huzarski Tomasz, Lener Marcin, Jakubowska Anna, Pietrzak Sandra, Szwiec Marek, Stawicka-Niełacna Małgorzata, Godlewski Dariusz, Prusaczyk Artur, Jasiewicz Andrzej, Kluz Tomasz, Tomiczek-Szwiec Joanna, Kilar-Kobierzycka Ewa, Siołek Monika, Posmyk Renata, Jarkiewicz-Tretyn Joanna, Scott Rodney, Narod Steven, Lubiński Jan
Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, ul. Unii Lubelskiej 1, Szczecin, 71-252, Poland.
Read-Gene, Dobra (Szczecińska), ul. Alabastrowa 8, Grzepnica, 72-003, Poland.
Hered Cancer Clin Pract. 2024 Sep 19;22(1):19. doi: 10.1186/s13053-024-00291-7.
To investigate whether Molybdenum blood level is a marker of cancer risk on BRCA1 carriers.
A prospective cohort study was conducted among 989 initially unaffected women with a BRCA1 mutation. Blood samples were collected to measure molybdenum levels, and participants were followed for an average of 7.5 years. Cox proportional hazards models were used to assess the association between blood molybdenum levels and cancer incidence, adjusting for potential confounders.
High blood molybdenum levels (> 0.70 µg/L) were significantly associated with an increased risk of developing ovarian cancer (HR = 5.55; 95%CI: 1.59-19.4; p = 0.007) and any cancer (HR = 1.74; 95%CI: 1.17-2.61; p = 0.007) but not breast cancer (HR = 1.46, CI = 0.91-2.33; p = 0.12). The cumulative incidence of ovarian cancer at ten years was 1.2% for the lowest molybdenum tertile, 4.2% for the middle tertile, and 8.7% for the highest tertile.
Elevated blood molybdenum levels are associated with an increased risk of ovarian cancer on BRCA1 mutation carriers. Lowering molybdenum levels may potentially reduce cancer risk in this population, and high molybdenum levels could serve as a marker for considering preventive oophorectomy in BRCA1 carriers. Further research is warranted to confirm these findings and explore interventions targeting molybdenum levels as a preventive measure for ovarian cancer in BRCA1 mutation carriers.
研究钼血水平是否为BRCA1基因携带者癌症风险的标志物。
对989名最初未受影响的BRCA1基因突变女性进行了一项前瞻性队列研究。采集血样以测量钼水平，并对参与者平均随访7.5年。使用Cox比例风险模型评估血钼水平与癌症发病率之间的关联，并对潜在混杂因素进行调整。
高血钼水平（>0.70μg/L）与卵巢癌发病风险增加（HR = 5.55；95%CI：1.59 - 19.4；p = 0.007）及任何癌症发病风险增加（HR = 1.74；95%CI：1.17 - 2.61；p = 0.007）显著相关，但与乳腺癌无关（HR = 1.46，CI = 0.91 - 2.33；p = 0.12）。钼水平最低三分位数组十年卵巢癌累积发病率为1.2%，中间三分位数组为4.2%，最高三分位数组为8.7%。
血钼水平升高与BRCA1基因突变携带者卵巢癌风险增加相关。降低钼水平可能会降低该人群的癌症风险，高钼水平可作为考虑对BRCA1基因携带者进行预防性卵巢切除术的一个标志物。有必要进一步研究以证实这些发现，并探索针对钼水平的干预措施作为BRCA1基因突变携带者卵巢癌的预防手段。
